ATE331527T1 - Verfahren zur behandlung von brustdrüsenerkrankungen - Google Patents

Verfahren zur behandlung von brustdrüsenerkrankungen

Info

Publication number
ATE331527T1
ATE331527T1 AT03815338T AT03815338T ATE331527T1 AT E331527 T1 ATE331527 T1 AT E331527T1 AT 03815338 T AT03815338 T AT 03815338T AT 03815338 T AT03815338 T AT 03815338T AT E331527 T1 ATE331527 T1 AT E331527T1
Authority
AT
Austria
Prior art keywords
treating breast
gland diseases
breast gland
diseases
treating
Prior art date
Application number
AT03815338T
Other languages
English (en)
Inventor
Mitchell F Brin
Stephen Donovan
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32867445&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE331527(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of ATE331527T1 publication Critical patent/ATE331527T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Processing Of Meat And Fish (AREA)
  • Jellies, Jams, And Syrups (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
AT03815338T 2002-02-08 2003-02-04 Verfahren zur behandlung von brustdrüsenerkrankungen ATE331527T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/071,826 US7838007B2 (en) 1999-12-07 2002-02-08 Methods for treating mammary gland disorders

Publications (1)

Publication Number Publication Date
ATE331527T1 true ATE331527T1 (de) 2006-07-15

Family

ID=32867445

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03815338T ATE331527T1 (de) 2002-02-08 2003-02-04 Verfahren zur behandlung von brustdrüsenerkrankungen

Country Status (12)

Country Link
US (2) US7838007B2 (de)
EP (3) EP1728517A3 (de)
JP (2) JP4889220B2 (de)
AT (1) ATE331527T1 (de)
AU (1) AU2003225549B2 (de)
BR (1) BR0307496A (de)
CA (1) CA2478902C (de)
DE (1) DE60306505T2 (de)
DK (1) DK1492561T3 (de)
ES (1) ES2264041T3 (de)
PT (1) PT1492561E (de)
WO (1) WO2004071525A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7838007B2 (en) * 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating mammary gland disorders
US7838008B2 (en) * 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating diverse cancers
EP1365800B1 (de) * 2000-06-28 2013-03-06 Ira Sanders Methoden zur verwendung von tetanustoxin zur therapeutischen anwendung bei lebewesen (säugetieren)
US20120114697A1 (en) * 2002-08-19 2012-05-10 Ira Sanders Treatment of holocrine gland dysfunction with clostridia neurotoxins
US7824693B2 (en) 2002-08-19 2010-11-02 Ira Sanders Treatment of fine wrinkles with clostridia neurotoxins
AU2003263860A1 (en) * 2002-08-19 2004-03-03 Ira Sanders Treatment of holocrine gland dysfunction with clostridia neurotoxins
WO2004066928A2 (en) * 2003-01-24 2004-08-12 Albert Einstein College Of Medicine Of Yeshiva University Use of mycobacterial vaccines in cd4+ or cd8+ lymphocyte-deficient mammals
CA2525367A1 (en) * 2003-05-09 2004-11-25 The Trustees Of The University Of Pennsylvania Use of citrate lyase inhibitors and tricarboxylate transporter inhibitors in the treatment of cancer
US8871224B2 (en) 2003-12-09 2014-10-28 Allergan, Inc. Botulinum toxin therapy for skin disorders
US8048423B2 (en) * 2003-12-09 2011-11-01 Allergan, Inc. Botulinum toxin therapy for skin disorders
US20050220734A1 (en) * 2004-04-02 2005-10-06 Allergan, Inc. Therapy for melanin related afflictions
US20070258900A1 (en) * 2004-07-20 2007-11-08 Joseph Francis Blood Flow Assessment of Clostridial Toxin Applications
EP1778078A2 (de) * 2004-07-20 2007-05-02 Allergan, Inc. Thermografische beurteilung von clostridientoxin-anwendungen
EP2298339B1 (de) * 2004-09-23 2015-07-15 Toxcure, Inc. Behandlung von Neoplasmen mit Neurotoxin
US8343929B2 (en) * 2004-09-23 2013-01-01 Toxcure, Inc. Treating neoplasms with neurotoxin
US20060073208A1 (en) * 2004-10-01 2006-04-06 Allergan, Inc. Cosmetic neurotoxin compositions and methods
US8155408B2 (en) * 2008-04-15 2012-04-10 General Electric Company Standardized normal database having anatomical phase information
ES2599033T3 (es) 2008-11-26 2017-01-31 Toxcure, Inc. Tratamiento de neoplasias con neurotoxina
WO2012074559A2 (en) 2010-12-02 2012-06-07 New York University Treatment of non-proliferative cystic disease
WO2012097189A1 (en) * 2011-01-13 2012-07-19 Rutgers, The State University Of New Jersey Systems and methods for multi-protocol registration and tissue classification using local morphologic scale (lms)
KR20140054055A (ko) 2011-07-14 2014-05-08 알러간, 인코포레이티드 성행위와 관련된 실금의 치료방법
EP2649985A1 (de) 2012-04-13 2013-10-16 Lipotec, S.A. Verbindungen zur Hemmung neuronaler Exozytose (III)
JP6470678B2 (ja) 2012-04-13 2019-02-13 ルブリゾル アドバンスド マテリアルズ， インコーポレイテッド ニューロンの開口分泌を阻害する化合物（ｉｉ）
EP2649983A1 (de) 2012-04-13 2013-10-16 Lipotec, S.A. Verbindungen zur Hemmung neuronaler Exozytose (II)
EP2649984A1 (de) 2012-04-13 2013-10-16 Lipotec, S.A. Verbindungen zur Hemmung neuronaler Exozytose
US11191819B2 (en) 2018-08-28 2021-12-07 Ira Sanders Skin therapeutics

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4664911A (en) 1983-06-21 1987-05-12 Board Of Regents, University Of Texas System Immunotoxin conjugates employing toxin B chain moieties
US5183462A (en) * 1990-08-21 1993-02-02 Associated Synapse Biologics Controlled administration of chemodenervating pharmaceuticals
US5466672A (en) 1992-12-04 1995-11-14 Ophidian Pharmaceuticals, Inc. Therapeutic use of clostridium difficile toxin A
US5437291A (en) 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
US6974578B1 (en) * 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
ATE215832T1 (de) 1994-05-09 2002-04-15 William J Binder Botulinumtoxin zur reduktion von migraine - kopfschmerzen
US5670484A (en) * 1994-05-09 1997-09-23 Binder; William J. Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders
US5595740A (en) 1994-05-16 1997-01-21 University Of Florida Cloning of non-IgA FC binding forms of the group B streptococcal beta antigens
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
US6143037A (en) * 1996-06-12 2000-11-07 The Regents Of The University Of Michigan Compositions and methods for coating medical devices
GB9617671D0 (en) 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
ES2268567T5 (es) * 1997-07-15 2010-11-02 The Regents Of The University Of Colorado Uso de terapia de neurotoxinas para el tratamiento de la retencion urinaria.
US6063768A (en) * 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
GB9721189D0 (en) 1997-10-08 1997-12-03 Speywood Lab The Limited Analgesic conjugates
DE19802569A1 (de) 1998-01-23 1999-09-09 Univ Albert Ludwigs Freiburg Toxikologisch aktive Fragmente des lethalen Toxins von Clostridium sordellii und deren Verwendung in Immuntoxinen
GB9818548D0 (en) 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
TW574036B (en) 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
ATE314859T1 (de) 1998-10-27 2006-02-15 Mayo Foundation Botulinumtoxine zur verstärkung der wundheilung
DE19852981A1 (de) 1998-11-17 2000-05-18 Martin Schmidt Botulinum-Toxine, deren Derivate, Analoge und molekulare Bruchstücke zur topischen epicutanen Anwendung auch in Zusammenwirken mit hautpenetrationsfördernden Substanzen und Maßnahmen in Zubereitungsformen zur Beeinflussung acetylcholinabhängiger Körperfunktionen
DE19856052A1 (de) 1998-12-04 2000-06-08 Deutsches Krebsforsch Konjugat zur Anreicherung in neuronalen Zellen
GB9907429D0 (en) 1999-03-31 1999-05-26 Microbiological Res Authority Modulation of C-fibre activity
ES2320849T3 (es) 1999-04-16 2009-05-29 Marvin Schwartz Procedimiento para reducir la perdida del cabello y estimular el crecimiento del mismo.
DE19925739A1 (de) 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
GB9922554D0 (en) 1999-09-23 1999-11-24 Microbiological Res Authority Inhibition of secretion from non-neuronal cells
US6113915A (en) 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US6265379B1 (en) 1999-10-13 2001-07-24 Allergan Sales, Inc. Method for treating otic disorders
US7838007B2 (en) * 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating mammary gland disorders
US6139845A (en) * 1999-12-07 2000-10-31 Allergan Sales, Inc. Method for treating cancer with a neurotoxin
US6143306A (en) 2000-01-11 2000-11-07 Allergan Sales, Inc. Methods for treating pancreatic disorders
US6261572B1 (en) 2000-01-11 2001-07-17 Allergan Sales, Inc. Method for treating a pancreatic disorder with a neurotoxin
US6641820B1 (en) 2000-01-19 2003-11-04 Allergan, Inc. Clostridial toxin derivatives and methods to treat pain
US6306423B1 (en) 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
AU2001276005A1 (en) 2000-08-02 2002-02-13 Allergan Sales, Inc. Method for treating a neoplasm
US6831059B2 (en) 2000-10-20 2004-12-14 Allergan, Inc. Compositions and methods for treating gonadotrophin related illnesses

Also Published As

Publication number Publication date
BR0307496A (pt) 2005-06-28
EP1728517A3 (de) 2008-06-25
PT1492561E (pt) 2006-10-31
AU2003225549B2 (en) 2006-11-16
US7846456B2 (en) 2010-12-07
DE60306505T2 (de) 2007-01-11
EP1492561B1 (de) 2006-06-28
AU2003225549A1 (en) 2004-09-06
CA2478902C (en) 2012-05-01
WO2004071525A1 (en) 2004-08-26
DK1492561T3 (da) 2006-09-25
JP2012025775A (ja) 2012-02-09
JP4889220B2 (ja) 2012-03-07
DE60306505D1 (de) 2006-08-10
EP2204183A1 (de) 2010-07-07
ES2264041T3 (es) 2006-12-16
US7838007B2 (en) 2010-11-23
US20050260231A1 (en) 2005-11-24
US20020094339A1 (en) 2002-07-18
EP1728517A2 (de) 2006-12-06
CA2478902A1 (en) 2004-08-26
JP2006510723A (ja) 2006-03-30
EP1492561A1 (de) 2005-01-05

Similar Documents

Publication Publication Date Title
ATE331527T1 (de) Verfahren zur behandlung von brustdrüsenerkrankungen
ATE493433T1 (de) Neue zusammensetzung und verfahren zur behandlung von immunerkrankungen
ATE522229T1 (de) Anti-ngf-antikörper zur behandlung verschiedener erkrankungen
BR9502707A (pt) Composto composição farmacêutica e método para o tratamento de uma afecção
DE602006016934D1 (de) Verfahren und zusammensetzungen zur behandlung von zns-erkrankungen
DE602004020263D1 (de) Amino-substituierte diaryläa,dücyclohepten- analoga als muscarinische agonisten und verfahren zur behandlung von neuropsychiatrischen erkrankungen
ATE521357T1 (de) Verfahren zur behandlung von hepatitis
DE60124080D1 (de) Verbindungen und verfahren zur behandlung der alzheimerschen krankheit
DE60330889D1 (de) Botulinum toxin zur behandlung von magengeschwür und gastroösophagealen reflux
DE69535498D1 (de) Verfahren zur behandlung vaskulärer kopfschmerzen
DE60027732D1 (de) Verwendung von anti-rubeola antkörpern zur behandlung von symptomen von erkrankungen des zentralen nervensystems
ATE383853T1 (de) Arylessigsäuren und verwandte verbindungen zur behandlung von alzheimer-krankheit
DE602004021847D1 (de) Verfahren zur prävention und behandlung von diabetes mit neurturin
ATE428413T1 (de) Neue verwendung von peptidverbindungen zur behandlung ovn zentralen neuropathischen schmerzen
ATE448775T1 (de) Rifalazil zur behandlung von infektionen mit clostridium difficile
DE60034871D1 (de) Verfahren und zusammensetzungen zur prevention oder behandlung von krebs und von krebs assoziertem knochenverlust
DE602004002394D1 (de) (3-ä3-'(2,4-BIS-TRIFLUORMETHYL-BENZYL)-(5-ETHYL-PYRIMIDIN-2-YL)-AMINOÜ-PROPOXYü-PHENYL)-ESSIGSÄURE UND VERWANDTE VERBINDUNGEN ALS MODULATOREN VON PPARS UND VERFAHREN ZUR BEHANDLUNG VON STOFFWECHSELSTÖRUNGEN
DE602004019897D1 (de) Verfahren zur racematspaltung von 2,4-diamino-3,6-dihydro-1,3,5-triazinen, die sich zur behandlung vkrankungen eignen
DE60333205D1 (de) Histaminika zur behandlung von allergischer rhinitis
DE602004023100D1 (de) Verbindungen und verfahren zur behandlung von dyslipidemie
ATE213163T1 (de) Verfahren zur behandlung von motorischen defiziten
ATE298246T1 (de) Aktiviertes protein c zur behandlung von pankreatitis
ATE346597T1 (de) Carbamate verbindungen zur behandlung oder verhutung von psychotischen krankheiten
ATE406171T1 (de) Aplidine zur behandlung von multiplem myelom
DE602005027228D1 (de) Zusammensetzungen und verfahren zur behandlung von krankheiten, die durch infektion mit yersinia spp ausgelöst sind

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1492561

Country of ref document: EP